The Development and Role of Capmatinib in the Treatment of MET-Dysregulated Non-Small Cell Lung Cancer—A Narrative Review

SIMPLE SUMMARY: In this narrative review, we discuss the development of capmatinib, a reversible MET tyrosine kinase inhibitor that received approval for advanced non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutation. Capmatinib was first discovered in 2011 and has been shown to...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsu, Robert, Benjamin, David J., Nagasaka, Misako
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10377299/
https://www.ncbi.nlm.nih.gov/pubmed/37509224
http://dx.doi.org/10.3390/cancers15143561

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10377299/
https://www.ncbi.nlm.nih.gov/pubmed/37509224
http://dx.doi.org/10.3390/cancers15143561

Ejemplares similares